Download PDF
Thromb Haemost 1970; 24(03/04): 438-449
DOI: 10.1055/s-0038-1654253
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Enhancement of ADP-Induced Platelet Aggregation by Exercise Test in Coronary Patients and Its Prevention by Pyridinolcarbamate

H Yamazaki
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University School of Medicine, Yushima, Tokyo, Japan
,
I Kobayashi
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University School of Medicine, Yushima, Tokyo, Japan
,
T Shimamoto
1   Institute for Cardiovascular Diseases, Tokyo Medical and Dental University School of Medicine, Yushima, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

ADP-induced platelet aggregation in citrated platelet rich plasma (CPRP) was examined using a photoelectric system. To exclude a variation in intensities of platelet aggregation in repeated measurements and to compare intensities of different samples, the maximum deflection of the optical density of CPRP induced by adding ADP solution was divided by a deflection of the optical density of the platelet free plasma and its value, shown as a percentage, was defined as an intensity of ADP-induced platelet aggregation. In this method, the linearity was found in the dose response curve of the platelet aggregation induced by 10−6, 3 × 10−6 and 10−5 molar of ADP with statistical significance. These variation coefficients were less than 5% in the responses induced by the higher doses of ADP. Changes in the ADP-induced platelet aggregation after a Master’s two step test were examined in 13 patients with angina pectoris 3 h after oral administration of placebo or 1 g of pyridinolcarbamate. Under placebo pretreatment, an enhancement of platelet aggregation was observed 1 min after the exercise test with statistical significance (P < 0.01 ∼ 0.05). In the cases of the same subjects pretreated with pyridinolcarbamate, such change was not observed at any time. Using a parallel line assay, an inhibitory effect of pyridinolcarbamate against enhancement of ADP-induced platelet aggregation after the exercise was also recognized with statistical significance (P < 0.01). In the 10 healthy volunteers, there was no statistically significant enhancement of ADP-induced platelet aggregation using any concentration of ADP 1 to 10 min after the exercise test.

 

  • References

  • 1 Born G. V. R. Quantitative investigations into aggregation of blood platelet. J. Physiol 162: 67 1962;
    PubMedSearch in Google Scholar
  • 2 Born G. V. R, Gross M. J. The aggregation of blood platelets. J. Physiol 168: 178 1963;
    CrossrefPubMedSearch in Google Scholar
  • 3 Born G. V. R, Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 215: 1027 1967;
    CrossrefPubMedSearch in Google Scholar
  • 4 Guthbertson W. F. J, Mills D. C. B. A miniature nephelometer for the study of platelet clumping. J. Physiol 168: 29 1963;
    CrossrefPubMedSearch in Google Scholar
  • 5 Didisheim P, Sturm R. E, Owen Jr. C. A. Experiments on thrombosis and its prevention. Sherbrooke symposium on blood coagulation. Sherbrooke; Quebec: April 1970
    Search in Google Scholar
  • 6 Gaarder A, Jonsen J, Laland S, Hellem A, Owren P. A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192: 531 1961;
    CrossrefPubMedSearch in Google Scholar
  • 7 Hellem A. J. Platelet adhesiveness. In: Series Haematologica. Vol. I., 2 99 Munksgaard; Copenhagen: 1968
    Search in Google Scholar
  • 8 Henry R. L. Effect of pyridinolcarbamate on specific components of hemostasis in Cruz’s model. In: Atherogenesis, Proceedings of the First International Symposium on Atherogenesis, Thrombogenesis and Pyridinolcarbamate Treatment. Tokyo. May, 1969. Ed. by Shimamoto T, Numano F, Hales G. U, Perrin A. 75 Excerpta Medica Foundation; Amsterdam: 1969
    Search in Google Scholar
  • 9 Lyhhe A. W. J, Willoughby D. A, Korsche E. A. Thymic permeability factor: Its relationship to lymph-node permeability factor and its antagonism by pyridinolcarbamate (Anginin) and other anti-inflammatory agents. J. Path. Bact 94: 381 1967;
    CrossrefPubMedSearch in Google Scholar
  • 10 Master A. M. The two-step exercise electrocardiogram: a test for coronary insufficiency. Ann. Int. Med 32: 824 1950;
    PubMedSearch in Google Scholar
  • 11 Nagano K, Nakao M. Personal communication..
    PubMed
  • 12 Numano F, Katsu K, Takenobu M, Shimamoto T. Comparative studies on the preventive effect of pyridinolcarbamate and estrogen against aortic and coronary atherosclerosis of cholesterol-fed rabbits. Part II : Histoenzymatic studies. Acta Path. jap. (In press).
    PubMed
  • 13 O’Brien J. R. Platelet aggregation. Part 2. Some results from a new method of study. J. clin. Path 15: 452 1962;
    PubMedSearch in Google Scholar
  • 14 O’Brien J. R. Effects of salicylates on human platelet. Lancet I: 779 1968;
    PubMedSearch in Google Scholar
  • 15 Spector W. G, Willoughby D. A. The pharmacology of inflammation. 112 The English Universities Press; London: 1968
    Search in Google Scholar
  • 16 Shimamoto T. The relationship of edematous arterial reaction in arteries to atherosclerosis and thrombosis. J. Atheroscler. Res 03: 87 1963;
    CrossrefPubMedSearch in Google Scholar
  • 17 Shimamoto T, Numano F, Fujita T. Atherosclerosis-inhibiting effect of an antibradykinin agent, pyridinolcarbamate. Amer. Heart J 71: 2216 1966;
    PubMedSearch in Google Scholar
  • 18 Shimamoto T, Maezawa H, Yamazaki H, Atsumi T, Fujita T, Ishioka T, Sunaga T. Pyridinolcarbamate, a bradykinin antagonist in veins. Amer. Heart J HI: 297 1966;
    PubMedSearch in Google Scholar
  • 19 Shimamoto T. Experimental study on atherosclerosis - an attempt at its prevention and treatment. Acta Path. jap 19: 15 1969;
    PubMedSearch in Google Scholar
  • 20 Shimamoto T, Yamashita Y, Numano F, Sunaga T. The endothelial cell damage of preatheromatous and atheromatous lesions observed by scanning electron microscope. Proc. Jap. Acad 45: 761 1969;
    PubMedSearch in Google Scholar
  • 21 Tsuchiya M, Fuzishiro Y, Shishido T. Observations vitale de la thrombogénèse. In: Atherogenesis, Proceedings of the First International Symposium on Atherogenesis, Thrombogenesis and Pyridinolcarbamate Treatment. Tokyo. May, 1969. Ed. by Shimamoto T, Numano F, Hales C. N, Perrin A. 145 Excerpta Medica Foundation; Amsterdam: 1969
    Search in Google Scholar
  • 22 Yamazaki H, Murase H, Shimamoto T, Shimamoto T. Appearance of platelet-clumping substance in plasma from humans with thrombosis, infection or tissue destruction. Proc. Jap. Acad 44: 1066 1968;
    PubMedSearch in Google Scholar
  • 23 Yamazaki H, Sano T, Odakura T, Takeuchi K, Shimamoto T. Electrocardiographic and hematological changes by exercise test in coronary patients and pyridinolcarbamate pretreatment - a double blind crossover trial. Amer. Heart J 79: 640 1970;
    CrossrefPubMedSearch in Google Scholar
  • 24 Yamazaki H, Odakura T, Takeuchi K, Sano T. Adhesive platelet count and blood coagulability in myocardial infarction and cerebral thrombosis. Thrombos. Diathes. haemorrh. (Stuttg.). (In press.)
    PubMed
  • 25 Zahavi J, Dreyfuss F. An abnormal pattern of adenosine diphosphate-induced platelet aggregation in acute myocardial infarction. Thrombos. Diathes. haemorrh. (Stuttg.) 21: 76 1969;
    PubMedSearch in Google Scholar
  • 26 Zucker M. B. In: Blood platelet. Ed. by Johnson S. A, Monto R. W, Rebuck J. W, Horn R. G. 141 Little, Brown and Company; Boston: 1961
    Search in Google Scholar